Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1616-1631
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1616
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1616
Chronic hepatitis B[21] | Chronic hepatitis C[22] | NAFLD[3,24] | Cirrhosis[25,26] |
↓: Alistipes, Bacteroides, Asaccharobacter, Butyricimonas, Ruminococcus, Clostridium cluster IV, Parabacteroides, Escherichia/Shigella | ↓: Clostridiales Bifidobacterium | ↓: Prevotella | ↓: Lachnospiraceae |
↑: Megamonas, Lachnospiraceae, Clostridium sensustricto, Actinomyces | ↑: Bacteroidetes, Streptococcus, Lactobacillus | ↑: Proteobacteria, Fusobacteria, Erysipelotrichaceae,Enterobacteriaceae, Lachnospiraceae, Streptococcaceae, Escherichia, Shigella | ↑:Enterobacteriaceae, Veillonellaceae, Streptococcaceae |
Hepatitis B-related HCC[27] | NASH-related HCC[29] | Cirrhosis-related HCC[17] |
↓: Faecalibacterium, Ruminococcus, Ruminoclostridium | ||
↑: Escherichia, Shigella, Enterococcus | ↑: Clostridium, Corynebacterium Bacillus, Desulfovibrio, Rhodococcus | ↑: Epsilonproteobacteria, Actinobacteria, Clostridia, Fusobacterium, Oribacterium |
- Citation: Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631
- URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1616.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1616